Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
27 hedge funds and large institutions have $4.82M invested in Carisma Therapeutics in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 9 closing their positions.
0.52% more ownership
Funds ownership: 0% → 0.52% (+0.52%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 29 → 27 (-2)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
58% less capital invested
Capital invested by funds: $11.5M → $4.82M (-$6.73M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $22K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$396K |
| 2 |
SIM
Spark Investment Management
New York
|
+$309K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$139K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$75.6K |
| 5 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$47.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$2.27M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$2.1M |
| 3 |
Millennium Management
New York
|
-$222K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$151K |
| 5 |
DTL
Dynamic Technology Lab
Singapore
|
-$116K |
CARM Hedge Fund Activity: Q4 2016 in Review
27 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2016, worth a combined $4.82M — down 58% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CARM and 7 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $396K. The largest seller was Flagship Pioneering, cutting an estimated $2.27M.
- 27 institutional investors held Carisma Therapeutics (CARM) as of Q4 2016, down from 29 in Q3 2016.
- Funds reported $4.82M of Carisma Therapeutics stock for Q4 2016, down 58% quarter-over-quarter.
- 7 funds opened new Carisma Therapeutics positions in Q4 2016 and 9 closed out, a net change of -2 holders.
- The largest Carisma Therapeutics buyer in Q4 2016 was Oxford Asset Management, an estimated $396K added.
- The largest Carisma Therapeutics seller in Q4 2016 was Flagship Pioneering, an estimated $2.27M sold.
Based on aggregated 13F filings for Q4 2016.